Article

Dr. Tashjian joins Potentia scientific advisory board

Louisville, KY-Potentia Pharmaceuticals has appointed Armen H. Tashjian Jr., MD, to its scientific advisory board.

Louisville, KY-Potentia Pharmaceuticals has appointed Armen H. Tashjian Jr., MD, to its scientific advisory board.

Dr. Tashjian is an emeritus professor of biological chemistry and molecular pharmacology, Harvard Medical School, Boston, where his research focuses on the biochemical and molecular mechanisms of signal transduction with an emphasis on neuropeptides and their receptors.

A second long-term interest has been on intracellular and extracellular calcium metabolism and skeletal biology and pharmacology. Dr. Tashjian founded the Department of Molecular and Cellular Toxicology at the Harvard School of Public Health, where he is an emeritus professor of toxicology. Under his guidance, this department was at the forefront of discovering mechanisms of toxicity of environmental chemicals and therapeutic agents.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.